Amy Comstock Rick, the new director of strategic coalitions for the FDA's Rare Disease Innovation Hub

November 4, 2024 03:14 PM EST

Rare disease biopharma companies weigh in on FDA's new innovation hub

Zachary Brennan

Senior Editor

AstraZeneca’s Alexion, BridgeBio, BioMarin, Ultragenyx and others, including Sen. Bob Casey (D-PA), recently weighed in on the details of a new cross-cutting FDA collaboration hub …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Rare disease biopharma companies weigh in on FDA's new innovation hub

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Rare dis­ease bio­phar­ma com­pa­nies weigh in on FDA's new in­no­va­tion hub

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Rare disease biopharma companies weigh in on FDA's new innovation hub